SUBSCRIBE
SUBSCRIBE

Government

Drug Development
Biopharma Update on the Novel Coronavirus: June 1
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 1, 2020.
May 28, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: May 29
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 29, 2020.
May 28, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 28
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
May 28, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Policy
Recalls Could be Imminent After FDA Discovers Carcinogens in Popular Diabetes Drug
The tests revealed that some metformin products contained the presence of N-nitrosodimethylamine (NDMA) levels above the acceptable daily intake levels established by the regulatory agency.
May 28, 2020
 · 
2 min read
 · 
Alex Keown
Business
What Masks Can and Can’t Do, and Why You Should Wear One
Michael Bell, M.D., deputy director of the Division of Healthcare Quality Promotion at the Centers for Disease Control, teamed up with the Pandemic Action Network to help answer such questions and combat misinformation.
May 27, 2020
 · 
4 min read
 · 
Gail Dutton
Policy
Biopharma Update on the Novel Coronavirus: May 27
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020.
May 27, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
FDA
BMS’ Opdivo and Yervoy Combination Treatment Snags Two Approvals in Lung Cancer this Month
Bristol Myers Squibb is doing its best to claim market share in the checkpoint inhibitor space and over the past month, the company is pushing its way forward with a pair of regulatory approvals in lung cancer.
May 27, 2020
 · 
2 min read
 · 
Alex Keown
FDA
Sanofi and Regeneron’s Dupixent Scores Another Approval for Dermatitis, This Time in Kids
To date, Dupixent is the only biologic approved for this age group.
May 26, 2020
 · 
3 min read
 · 
Mark Terry
Lumasiran was granted priority review status by FD
Policy
FDA Grants Priority Review to Alnylam’s RNAi Therapy Lumasiran for Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals’ lumasiran for a chronic kidney stone disease was granted Priority Review status by the U.S. Food and Drug Administration. It will have a target action date of December 3, 2020.
May 26, 2020
 · 
3 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: May 26
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 26, 2020.
May 26, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Load More
PRESS RELEASES
Press Releases
Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments
January 9, 2026
 · 
5 min read
Press Releases
Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
December 22, 2025
 · 
10 min read
Press Releases
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
December 22, 2025
 · 
6 min read
Press Releases
Genentech Announces Agreement With U.S. Government
December 22, 2025
 · 
2 min read
Press Releases
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
December 22, 2025
 · 
5 min read
Press Releases
Boehringer Ingelheim announces broad agreement with the U.S. Government to lower the cost of medicines for American patients and expand its U.S. footprint
December 22, 2025
 · 
3 min read
Press Releases
AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS
December 22, 2025
 · 
8 min read
Press Releases
Novartis and US government reach agreement on lowering drug prices in the US
December 22, 2025
 · 
5 min read
Press Releases
Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
December 22, 2025
 · 
7 min read
Press Releases
Canada secures African swine fever zoning arrangement with the Philippines
December 17, 2025
 · 
4 min read
Press Releases
Perspectum and InHealth Announce National Diagnostics Partnership to Boost Oxford CDC Capacity and Widen Access to Advanced MRI Across the UK
December 2, 2025
 · 
3 min read
Press Releases
Canada’s $1.5-billion Rare Disease Drug Strategy generating ‘return on investment’ for patients and society but more needs to be done
November 26, 2025
 · 
4 min read
Press Releases
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
November 7, 2025
 · 
15 min read
Press Releases
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
November 5, 2025
 · 
8 min read
Press Releases
Immutep Receives A$4.6 million R&D Tax Incentive from French Government
November 4, 2025
 · 
1 min read
Press Releases
EMD Serono Announces Unprecedented Agreement with U.S. Government to Expand Access to IVF Therapies
October 17, 2025
 · 
6 min read
Press Releases
AHF Commends Gov. Newsom for Signing PBM Reform Bill (SB 41, Weiner)
October 13, 2025
 · 
1 min read
Press Releases
Igyxos Biotherapeutics Awarded EUR 5.7 Million from the French Government to Accelerate Development of its First-in-class Monoclonal Antibody for the Treatment of Infertility
October 2, 2025
 · 
4 min read
Press Releases
VYLOY® (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer is now funded in both Ontario and Quebec
October 2, 2025
 · 
4 min read
Press Releases
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
September 22, 2025
 · 
3 min read
Load More